HWM
NKTR icon

HB Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

HB Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,244
Closed -$391K – 1579
2025
Q4 		$391K Hold
9,244
– – ﹤0.01% 1004
2025
Q3 		$526K Buy
+9,244
New +$306K ﹤0.01% 834
2025
Q2 		– Sell
-5,274
Closed -$53.8K – 1255
2025
Q1 		$53.8K Buy
5,274
+1,001
+23% +$13.1K ﹤0.01% 1192
2024
Q4 		$60.4K Buy
4,273
+1,306
+44% +$23K ﹤0.01% 1043
2024
Q3 		$57.9K Buy
+2,967
New +$56.6K ﹤0.01% 947

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HB Wealth Management's NKTR Position: Q1 2026 in Review

HB Wealth Management sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 9,244 shares — an estimated $391K sold.

HB Wealth Management first reported a position in NKTR in Q3 2024 and held it in 5 quarters. The position peaked at $526K in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • HB Wealth Management reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HB Wealth Management sold 9,244 Nektar Therapeutics shares in Q1 2026, an estimated $391K.
  • HB Wealth Management first reported a position in Nektar Therapeutics in Q3 2024 and held it in 5 quarters.
  • HB Wealth Management's Nektar Therapeutics position peaked at $526K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on HB Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.